Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOLX 
Hologic Inc (HOLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: HOLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $76.5
1 Year Target Price $76.5
| 3 | Strong Buy |
| 3 | Buy |
| 14 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.89% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.68B USD | Price to earnings Ratio 30.06 | 1Y Target Price 76.5 |
Price to earnings Ratio 30.06 | 1Y Target Price 76.5 | ||
Volume (30-day avg) 20 | Beta 0.7 | 52 Weeks Range 51.90 - 80.31 | Updated Date 12/1/2025 |
52 Weeks Range 51.90 - 80.31 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When After Market | Estimate 1.1 | Actual 1.13 |
Profitability
Profit Margin 13.8% | Operating Margin (TTM) 32.74% |
Management Effectiveness
Return on Assets (TTM) 7.3% | Return on Equity (TTM) 11.12% |
Valuation
Trailing PE 30.06 | Forward PE 16.39 | Enterprise Value 17135304943 | Price to Sales(TTM) 4.07 |
Enterprise Value 17135304943 | Price to Sales(TTM) 4.07 | ||
Enterprise Value to Revenue 4.18 | Enterprise Value to EBITDA 15.6 | Shares Outstanding 222905228 | Shares Floating 219218376 |
Shares Outstanding 222905228 | Shares Floating 219218376 | ||
Percent Insiders 1.01 | Percent Institutions 99.8 |
Upturn AI SWOT
Hologic Inc
Company Overview
History and Background
Hologic Inc. was founded in 1985 and is based in Marlborough, Massachusetts. It initially focused on bone densitometry and has grown through acquisitions and internal development to become a leader in women's health, diagnostics, and surgical solutions.
Core Business Areas
- Diagnostics: Develops and manufactures diagnostic products for infectious diseases, cytology, and molecular diagnostics.
- Breast and Skeletal Health Solutions: Offers a range of breast health products, including mammography systems, breast biopsy systems, and bone densitometry systems.
- Surgical: Provides minimally invasive surgical products for gynecologic and reproductive health procedures.
Leadership and Structure
The current CEO of Hologic Inc. is Stephen P. MacMillan. The company has a traditional corporate structure with executive leadership overseeing various business units and functions.
Top Products and Market Share
Key Offerings
- Panther System: A fully automated, integrated molecular diagnostics platform. Competitors include Roche, Abbott, and Siemens. Hologic held a significant share of the women's health molecular diagnostics market, estimated around 40%.
- Genius 3D Mammography: Digital breast tomosynthesis system for breast cancer screening. Competitors include GE Healthcare, Siemens Healthineers, and Fujifilm. Hologic's market share in digital breast tomosynthesis is substantial, estimated above 30% in the US.
- MyoSure System: A hysteroscopic tissue removal system used for the treatment of abnormal uterine bleeding. Competitors include Medtronic and Boston Scientific. Revenue generated from this product is substantial.
Market Dynamics
Industry Overview
The medical device and diagnostics industry is characterized by innovation, stringent regulation, and increasing demand driven by an aging population and growing healthcare awareness.
Positioning
Hologic Inc. holds a strong position in the women's health market, with competitive advantages in molecular diagnostics and breast health technologies.
Total Addressable Market (TAM)
The global women's health market is estimated to be worth over $40 billion. Hologic is well-positioned to capture a significant portion of this TAM through its established product portfolio and ongoing innovation.
Upturn SWOT Analysis
Strengths
- Strong brand reputation in women's health
- Leading market positions in key segments
- Innovative product portfolio
- Established distribution network
Weaknesses
- Reliance on specific market segments
- Exposure to regulatory risks
- Potential for product liability claims
- Vulnerable to competition
Opportunities
- Expanding into emerging markets
- Developing new diagnostic and therapeutic solutions
- Acquiring complementary businesses
- Capitalizing on technological advancements
Threats
- Intense competition
- Pricing pressures
- Changes in healthcare regulations
- Economic downturns
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Danaher (DHR)
- Abbott (ABT)
- Siemens Healthineers (SEMHF)
Competitive Landscape
Hologic Inc. competes with large, diversified healthcare companies. Its strength lies in its focus on women's health and innovative product offerings.
Major Acquisitions
Biotheryx
- Year: 2024
- Acquisition Price (USD millions): 85
- Strategic Rationale: Enhance diagnostic portfolio
Somatex Medical Technologies GmbH
- Year: 2023
- Acquisition Price (USD millions): 280
- Strategic Rationale: Enhance Breast and Skeletal Health division
Growth Trajectory and Initiatives
Historical Growth: Hologic Inc. has experienced significant growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued growth for Hologic Inc. driven by increasing demand for women's health products and services.
Recent Initiatives: Recent initiatives include the acquisition of Biotheryx, and continued investment in research and development.
Summary
Hologic is a financially strong company with a leadership position in women's health. It has a solid revenue base and strong profit margins. The company's focus on strategic acquisitions enhances its innovation and growth. However, increasing competition and evolving healthcare regulations pose potential challenges and should be monitored.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Market Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | Chairman, CEO & President Mr. Stephen P. MacMillan | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7070 | Website https://www.hologic.com |
Full time employees 7070 | Website https://www.hologic.com | ||
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.